

Shlomo Keidar

Curriculum Vitae

Date and place of birth: July 4, 1946; Nove-Zamky, Czechoslovakia (ID # 3013657-6)
Married, 4 children

Education:

| | | | |
|------|--|----------|------|
| 1967 | Faculty of Medicine, Bologna, Italy | Medicine | |
| 1971 | Technion – Israel Institute of Technology, Haifa | Medicine | M.D. |

Academic and professional appointments:

| | | | |
|--------------|--|---------------------|-------------------|
| 1974-1978 | Carmel Medical Center, Haifa | Resident | Internal Medicine |
| 1978-1982 | Carmel Medical Center, Haifa | Resident | Cardiology |
| 1984–1986 | Rambam Medical Center, Haifa | Clin. Instructor | Medicine |
| 1987-1994 | Technion – Israel Institute of Technology, Haifa | Clin. Sen. Lecturer | Internal Medicine |
| 1987-1989 | Washington University School of Medicine, St. Louis, MO, USA, | Visiting Scientist | Internal Medicine |
| 1994-to date | Technion – Israel Institute of Technology, Haifa | Assoc. Clin. Prof. | Internal Medicine |

Competitive grants:

| | |
|--------------|---|
| 2004-2006 | ICON. The effect of Irbesartan on hypertension. \$30,000. |
| 2004-2006 | PPD. The effect of Norvasc on hypertension. \$30,000. |
| 2004-2005 | Dexxon. The effect of Simvastatin on blood lipids. \$30,000. |
| 2002-2004 | Pharmacia Grant: Role of Eplereone in atherosclerosis. \$75,000. |
| 2000-2002 | Niiderzahren Grant: IL-6 in Atherosclerosis. DM100,000 |
| 1998-2002 | BMS. A multicenter study comparing the effect of Omapatrilat vs. Enalapril on the morbidity and mortality of patients with severe CHF. \$400,000. |
| 1998-to date | Novartis. Valsartan antihypertensive long-term use evaluation (VALUE) trial of cardiovascular events in hypertension. \$150,000. |

Significant Publications in peer-reviewed journals:

Keidar S, Attias J, Coleman R, Wirth K, Scholkens B, Hayek T. Attenuation of atherosclerosis in apolipoprotein E deficient mice by Ramipril is dissociated from its antihypertensive effect and from ostentation of bradykinin. *J cardiovas Pharmacol.* 2000;35:64–72.

Hayek T, Aviram M, Heinrich RT, Sakhnini E, **Keidar S**. Losartan Inhibits Cellular Uptake of Oxidized LDL by Monocyte – Macrophages from Hypercholesterolemic Patients. *Biochem Biophys Res comm.* 2000;273:417-420.

Keidar S, Heinrich RT, Kaplan M, Hayek T, Aviram M. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. *Arterioscler Thromb Vasc Biol.* 2001;21(9):1464-1469.

Keidar S, Heinrich RT, Kaplan M, Aviram M. Oxidative stress increases the expression of the angiotensin-II receptor type 1 in mouse peritoneal macrophages. *J Renin Angiotensin Aldosterone Syst.* 2002;3(1):24-30.

Kaplan M, Aviram M, Knopf C, **Keidar S**. Angiotensin II reduces macrophage cholesterol efflux: a role for the AT-1 receptor but not for the ABC1 transporter. *Biochem Biophys Res Commun.* 2002;290(50):1529-1534.

Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: A possible role for Angiotensin-Converting enzyme and the receptors of Angiotensin II and Aldosterone. *Circulation.* 2004;109(18):2213-2220.

Hayek T, Hussein K, Aviram M, Coleman R, **Keidar S**, Pavlotzky E, Kaplan M.

- Macrophage-foam cell formation in streptozotocin-induced diabetic mice: Stimulatory effect of glucose. *Atherosclerosis*. 2005;183(1):25-33.
- Karram T, Abbasi A, **Keidar S**, Golomb E, Hochberg I, Winaver J, Hoffman A. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. *Am J Physiol Heart Circ Physiol*. 2005;289(4):H1351-1358.
- Keidar S**, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T, Karry R, Abassi Z. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. *Circ Res*. 2005;97(9):946-953.
- T Hayek, K Hussein, M Aviram, R Coleman, **S Keidar**, E Pavlotzky, M Kaplan. Macrophage-foam cell formation in streptozotocin-induced diabetic mice: Stimulatory effect of glucose. *Atherosclerosis*. 2005;283:25-33.
- S Keidar**, A Strizevsky, A Raz, A Gamliel-Lazarovich. ACE2 activity is increased in monocytes derived macrophages from prehypertensive subjects. *Nephrol Dial Transplant* 22(2):597-601, 2007.

Book chapters and invited reviews:

- S Keidar. Angiotensin, LDL peroxidation and atherosclerosis. *Life Sciences*. 1998;63(1),1-11.
- S Keidar. Angiotensin II and atherosclerosis. *Receptors in cardiovasc dis*. 1999;5-8.

Graduate students:

- Yitzak Kinnog, MD thesis, 1992
- Adi Leiba, MD thesis, 1995
- Merav Leiba, MD thesis, 1995.
- Nir Shimoni, MD thesis, 2003.
- Eran Browner, MD thesis, 2005.
- Amit Ovental, MD thesis, 2005.
- Ido Bogner, postgraduate, 2006.

Invited lectures:

- ACE inhibition and AT1-receptor antagonists - The new agenda. 8th International Congress on Cardiovascular Pharmacotherapy. Amsterdam, Mar 1999.
- Angiotensin, LDL peroxidation and atherosclerosis. Israel Hypertension Society. Jul 1999.
- What role does angiotensin II play in development of atherosclerosis. Finnish Hypertension Society. Helsinki, May 2001.
- Angiotensin Receptor Blocker Advisory Board. 2003, 2004, 2005.
- ACE2 in congestive heart failure. European Heart Failure Society. Jan 2006.